Ulisses – Page 2 – Scilex Holding

11 Apr

SEC FIlings

Prospectus [Rule 424(b)(3)]

April 11, 2023
Posted by Ulisses

11 Apr

SEC FIlings

Current report

April 11, 2023
Posted by Ulisses

27 Mar

SEC FIlings

Additional definitive proxy soliciting materials and Rule 14(a)(12)

March 27, 2023
Posted by Ulisses

21 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 21, 2023
Posted by Ulisses

21 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 21, 2023
Posted by Ulisses

21 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 21, 2023
Posted by Ulisses

21 Mar

SEC FIlings

Current report

March 21, 2023
Posted by Ulisses

20 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 20, 2023
Posted by Ulisses

17 Mar

SEC FIlings

Notice of Effectiveness

March 20, 2023
Posted by Ulisses

17 Mar

SEC FIlings

Notice of Effectiveness

March 20, 2023
Posted by Ulisses

Posts by Ulisses

Prospectus [Rule 424(b)(3)]

Current report

Additional definitive proxy soliciting materials and Rule 14(a)(12)

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Current report

Prospectus [Rule 424(b)(3)]

Notice of Effectiveness

Notice of Effectiveness

Gloperba Launch – Nasdaq-2024

A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain

Gout Awareness Day – May 22

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch